MarginsXMarginsX
Home › Markets › Health Care › ABVC

ABVC BioPharma Inc. (ABVC)

ABVC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9400
+3.30% on the day
Market cap
$25.4M
Nano cap
Revenue · 2025
$296K
-41.9% on 2024
Net income · 2025
-$7.9M
-2671.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/0001213900-26-023063-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerABVC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001173313
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$296K
Net income-$7.9M
Operating income-$7.2M
Net margin-2671.8%
Operating margin-2416.0%
Revenue growth-41.9%
Cash$681K
Total assets$21.1M
P/E (computed)Net income was not positive
P/S (computed)85.7×

Warning signs

Cash runway
0.1 months
$11K cash at September 30, 2026
Share count, 1 year
+11.0%
2025-10-30 to 2026-11-09 · +273.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern."
10-Q 2026-11-10
Cash and burn$11K cash; operating cash flow -$541K a quarter.Report 2026-09-30
Shares outstanding26,976,625 (2026-11-09); 24,301,089 a year earlier; 7,231,940 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorSimon & Edward, LLP, Rowland Heights, California, United States; changed auditors 2 times in 24 months8-K 4.01 2026-07-02
Late filings, 12 months1 NT noticeNT 10-Q 2026-05-15
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed$1.1M-$439K$11K$30KNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$737K-$244K$32K$59KNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$1.6M-$894K$140K$89KNeeds four quarters10-Q 2026-05-18
Q4 2025
2025-12-31
-$500K-$2.8M-$588K$681K$756K$296K10-K 2026-03-03
Q3 2025
2025-09-30
$796K-$2.0M-$965K$192K$1.3MNeeds four quarters10-Q 2025-11-03
Q2 2025
2025-06-30
Not filed-$2.3M-$894K$388K$1.1MNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$842K-$540K$152K$810KNeeds four quarters10-Q 2026-05-18
Q4 2024
2024-12-31
$2K-$732K-$702K$248K$1.8M$510K10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B42026-11-13
Latest annual report
ANNUAL REPORT
10-K2026-03-03
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-10
Latest current report
CURRENT REPORT
8-K2026-11-02
Latest proxy
DEFINITIVE PROXY STATEMENT
DEF 14A2026-09-29

Source: SEC EDGAR submissions feed, 803 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.1%
1 month-7.0%
3 months-5.1%
Year to date-57.3%
1 year-67.5%
From 52-week high-68.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CRVOCervoMed Inc.$1.67-1.18%$25.3M
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
IMMPImmutep Limited$3.40-2.30%$25.1M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
IXHLIncannex Healthcare Inc.$1.93-2.03%$24.2M
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier